(Q73381707)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10645753%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

title

Dose linearity after oral administration of tacrolimus 1-mg capsules at doses of 3, 7, and 10 mg (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10645753%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

author name string

I Bekersky

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10645753%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

D Dressler

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10645753%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Q A Mekki

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10645753%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 December 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10645753%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

published in

Clinical Therapeutics

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10645753%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10645753%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10645753%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

2058-2064

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10645753%20AND%20SRC:MED&resulttype=core&format=json

Clinical pharmacokinetics of tacrolimus

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987237-9

7 January 2021

Tacrolimus: a new immunosuppressive agent.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987237-9

7 January 2021

Bioequivalence of a new strength tacrolimus capsule under development

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987237-9

7 January 2021

Consensus document: therapeutic monitoring of tacrolimus (FK-506).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987237-9

7 January 2021

Therapeutic drug monitoring of tacrolimus in clinical transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987237-9

7 January 2021

Tacrolimus oral bioavailability doubles with coadministration of ketoconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987237-9

7 January 2021

Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987237-9

7 January 2021

Tacrolimus (FK506): validation of a sensitive enzyme-linked immunosorbent assay kit for and application to a clinical pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987237-9

7 January 2021

A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2987237-9

7 January 2021

10.1016/S0149-2918(00)87237-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10645753%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference